Soleno Therapeutics, Inc.
SLNO
$73.64
$0.380.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -24.18% | 351.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.90% | 241.50% | |||
| Operating Income | 25.90% | -241.50% | |||
| Income Before Tax | 26.93% | -250.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 26.93% | -250.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 26.93% | -250.58% | |||
| EBIT | 25.90% | -241.50% | |||
| EBITDA | 26.07% | -246.73% | |||
| EPS Basic | 30.34% | -223.40% | |||
| Normalized Basic EPS | 29.94% | -245.55% | |||
| EPS Diluted | 30.34% | -220.96% | |||
| Normalized Diluted EPS | 29.94% | -245.55% | |||
| Average Basic Shares Outstanding | 4.89% | 8.41% | |||
| Average Diluted Shares Outstanding | 4.89% | 8.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||